Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 672-678

  Ding, Reinhard ^a   Frei, Eva ^b   Fardanesh, Mahmoudreza ^b   Schrenk, Hans Hermann ^b   Kremer, Paul ^c   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Asklepios Klinik   (Germany)

Author keywords

5 aminofluorescein; brain neoplasms; human serum albumin; pharmacokinetics

Indexed keywords

5 AMINOFLUORESCEIN HUMAN SERUM ALBUMIN; FLUORESCENT DYE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN TISSUE; BRAIN TUMOR; CLINICAL ARTICLE; COVALENT BOND; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GLIOBLASTOMA; HEMANGIOBLASTOMA; HUMAN; HUMAN TISSUE; KINETICS; MALE; MEDULLOBLASTOMA; OLIGODENDROGLIOMA; PREDICTION; STEADY STATE;

AGED; BRAIN NEOPLASMS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUORESCEINS; FLUORESCENT DYES; GERMANY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR PROBE TECHNIQUES; MONITORING, INTRAOPERATIVE; NEUROSURGICAL PROCEDURES; SERUM ALBUMIN; SPECTROMETRY, FLUORESCENCE; TISSUE DISTRIBUTION;

EID: 79955545004     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372626     Document Type: Article

References (17)

1. Kremer P, Wunder A, Sinn H, et al. Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results. Neurol Res. 2000 ; 22: 481-489 (Pubitemid 30602552)
2. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 ; 7: 392-401
3. Moore GE, Peyton WT. The clinical use of fluorescein in neurosurgery; the localization of brain tumors. J Neurosurg. 1948 ; 5: 392-398
4. Utsuki S, Miyoshi N, Oka H, et al. Fluorescence-guided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study 2. Brain Tumor Pathol. 2007 ; 24: 53-55 (Pubitemid 350165714)
5. Miyatake S, Kuroiwa T, Kajimoto Y, et al. Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report 2. Neurosurgery. 2007 ; 61: E1101 - E1103
6. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. 1998 ; 42: 518-525
7. Stehle G, Sinn H, Wunder A, et al. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs. 1997 ; 8: 677-685 (Pubitemid 27404725)
8. Parac-Vogt TN, Kimpe K, Laurent S, et al. Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity. Chemistry. 2005 ; 11: 3077-3086 (Pubitemid 40672465)
9. Hartung G, Stehle G, Sinn H, et al. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Clin Cancer Res. 1999 ; 5: 753-759 (Pubitemid 29180825)
10. Vis AN, van der Gaast A, van Rhijn BW, et al. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol. 2002 ; 49: 342-345 (Pubitemid 34253274)
11. Kremer P, Mahmoudreza F, Ding R, et al. Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery. 2009 ; 64: 53-60
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41
13. Gibaldi M, Perrier D Pharmacokinetics. 2 nd ed. New York, NY: Marcel Dekker ; 1982 :
14. Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm. 1988 ; 16: 475-492 (Pubitemid 19017475)
15. Benet LZ. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci. 1972 ; 61: 536-541
16. Beeken WL, Volwiler W, Goldsworthy PD, et al. Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest. 1962 ; 41: 1312-1333
17. Peters T All About Albumin: Biochemistry, Genetics and Medical Applications. San Diego, Calif: Academic Press ; 1996 :